贝达喹啉：现状与未来展望。

Bedaquiline: Current status and future perspectives.

机构信息

Clinical MicrobiologyResearch Center, Ilam University of Medical Sciences, Ilam, Iran.

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

J Glob Antimicrob Resist. 2021 Jun;25:48-59. doi: 10.1016/j.jgar.2021.02.017. Epub 2021 Mar 5.

DOI:10.1016/j.jgar.2021.02.017

PMID:33684606

Abstract

The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.

摘要

耐药结核病（TB）的发展是全球的主要威胁。根据世界卫生组织（WHO）的报告，估计每年有超过 500,000 例新的耐药结核病病例。此外，来自世界不同国家的报告显示，耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）的情况令人震惊。因此，需要新的结核病治疗方案。贝达喹啉（BDQ）是一种新型抗结核药物，对敏感和耐药结核病均具有显著的最低抑菌浓度（MIC）。此外，BDQ 最近被批准用于治疗耐多药结核病。本综述总结了有关 BDQ 耐药性的现有数据，描述了其抗菌特性，并为该新型抗结核药物的临床应用提供了新的视角。